BRUTASTRONG 200 Tablets

Product Details

• Product Name: BRUTASTRONG™ 200 Tablets
• Active Ingredient: The packaging clearly states “Cefpodoxime Proxetil Tablets IP”. This means the active pharmaceutical ingredient is Cefpodoxime Proxetil, and “IP” indicates it complies with the standards of the Indian Pharmacopoeia.
• Manufacturer/Brand: The logo at the top shows it is from HealthCare Mankind.
• Strength: “200” in the product name and on the packaging (BRUTASTRONG 200) signifies the dosage strength, meaning 200 mg of Cefpodoxime Proxetil per tablet.
• Formulation: Tablets.
• Price (MRP): The Maximum Retail Price is listed as ₹247.50 for a pack containing 10 Tabs (tablets).
• Packaging: The product includes a main outer box and blister packs containing the tablets. One blister pack is shown alongside the box.

General Information on Cefpodoxime Proxetil (as an antibiotic):

Cefpodoxime Proxetil is classified as a third-generation cephalosporin antibiotic. It is prescribed to treat a broad spectrum of bacterial infections.

Common Uses (as prescribed by a doctor):

• Respiratory Tract Infections: Such as acute exacerbations of chronic bronchitis, pneumonia, sinusitis, pharyngitis, and tonsillitis.
• Urinary Tract Infections (UTIs).
• Skin and Soft Tissue Infections.
• Acute Otitis Media (middle ear infections).
• It is often used when a higher strength (200mg) is deemed necessary by a physician for adult patients or specific types of infections.

Mechanism of Action:

Cefpodoxime Proxetil works by interfering with the synthesis of the bacterial cell wall, which ultimately leads to the destruction of the bacteria.

Important Considerations:

• As an antibiotic, BRUTASTRONG™ 200 Tablets are effective only against bacterial infections and will not provide relief for viral conditions like the common cold or flu.
• This medication should only be used under the guidance and prescription of a qualified healthcare professional. Misuse of antibiotics can lead to the development of antibiotic resistance and other adverse health outcomes.